Table: Brightpath Biotherapeutics - Q1 parent results

BrightPath Biotherapeutics Co

10/08/2023 07:01

Aug 10 (Reuters)- 
             Brightpath Biotherapeutics Co., Ltd. 
             PARENT-ONLY FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                 3 months ended      3 months ended        Year to  
                Jun 30, 2023        Jun 30, 2022      Mar 31, 2024  
                   LATEST             YEAR-AGO           LATEST     
                   RESULTS             RESULTS          FORECAST    
  Sales             0 mln               0 mln             0 mln     
                 (-84.2 pct)         (-50.0 pct)      (-100.0 pct)  
  Operating     loss 293 mln        loss 545 mln        loss 1.35   
  Recurring     loss 293 mln        loss 548 mln        loss 1.35   
  Net           loss 295 mln        loss 548 mln        loss 1.36   
  EPS           loss 4.70 yen       loss 9.75 yen    loss 21.58 yen 
  Ann Div                                NIL               NIL      
  -Q2 div                                NIL               NIL      
  -Q4 div                                NIL               NIL      
  
  NOTE - Brightpath Biotherapeutics Co., Ltd.. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T